Replies to post #7386 on Pluristem Therapeutics Inc (PSTI)

[Scott999]

"PLX-R18 is now undergoing second- and third-stage trials in the US with the support of the US National Institute of Health, the department of defense and the Food and Drug Administration"

Did I miss the start of the phase 3 trials? It's undergoing already? This article was written with the cooperation with Pluristem as it states at the end. So you would think if it WAS written in cooperation with them, they would see it before it gets published, to make sure what is said is accurate.

So it is either an outright lie, or it has started, in which case they epically failed to disclose. If that cooperation statement wasn't there I could care less as it's just someone making an error that always seems to occur. But it is there and that's what irks me. A lot of great stuff in there, but that point should never have been put in there.

[Scott999]

When looking at the benefits of Orphan Drug Designation yesterday I came across an articles which had the following paragraph.

There is an even greater potential for profit when drugs have multiple orphan disease indications or if they can later go on to be used for more widespread non-orphan indications; for example, Gleevec® from Novartis Oncology resulted in sales of $2.4 billion in 2010. In addition, a number orphan drugs are biologics, meaning they are less likely to have generic equivalents, which extends the value to sponsors even after patent expiration.

https://criteriuminc.com/wordpress/index.php/orphan-drug-development-why-they-are-so-important/

And from that article just posted

Aberman said this approval could fast-track the cell product use for other indications relating to damaged hematological systems, including failed bone-marrow transplants, blood disorders because of prolonged chemotherapy or radiation treatment, and genetic blood disorders or related cancers. Collectively, this would mean improved treatment for millions of people.

If they could just get this contract completed and get this phase 3 NHP trial started, other indications could come on line soon after upon having good results and getting it approved.

13000 in the U.S. alone have this type of blood disorder. It's was great to see quotes from Prof. Or, who actually administered the treatment. Sure all three died eventually, but to go from deathbed to discharged and having an extra 9 months (I believe) to live is amazing. And who knows, regular administration of PLX may have prolonged their life substantially more.

Cmon get this contract signed so we can get the Plx show on the road.